BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Begins Manufacturing of Lead Drug Candidate in Europe
Oct 9, 2020
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that its European manufacturer, BSP Pharmaceuticals S.p.A. (“BSP”), has begun the manufacturing process for Berubicin Drug Product, its lead drug candidate for the treatment of glioblastoma multiforme (“GBM”). GBM is an aggressive form of brain cancer currently considered incurable. “Our preparations for filing an IND for Berubicin require continued execution in both our clinical and manufacturing initiatives,” CNS Pharmaceuticals CEO John Climaco said in the news release. “With the manufacturing of our Berubicin Drug Product in Europe, we continue to advance closer toward an IND filing for Berubicin, which we expect to submit later this quarter. We have also made significant progress on the clinical front and recently engaged Worldwide Clinical Trials as the contract research organization, Image Analysis Group (‘IAG’) as the imaging partner, and Berry Consultants as a biostatistical advisor for our Phase 2 trial design. We have also added Dr. Patrick Wen, a renowned neuro-oncologist, to our Scientific Advisory Board. Our laser focus remains on initiating a U.S. Phase 2 trial for Berubicin in Q1 of 2021 and we continue to demonstrate our ability to execute our operational and clinical plans toward that goal.”
To view the full article, visit https://ibn.fm/bvtlq
About CNS Pharmaceuticals Inc.
CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase 1 clinical trial with Berubicin in malignant brain tumors, which Reata conducted in 2006. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. One patient experienced a durable complete response and remains cancer-free as of February 20, 2020. These Phase 1 results represent a limited patient sample size and, while promising, are not a guarantee that similar results will be achieved in subsequent trials. By the end of 2020, CNS expects to commence a Phase 2 clinical trial of Berubicin for the treatment of GBM in the U.S., while a sub-licensee partner undertakes a Phase 2 trial in adults and a first-ever Phase 1 trial in pediatric GBM patients in Poland. Its second drug candidate, WP1244, is a novel DNA binding agent that has shown in preclinical studies that it is 500 times more potent than the chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation. For more information, visit the company’s website at www.CNSPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]
BioMedWire is part of the InvestorBrandNetwork
More News
AI: 10 days that changed the course of artificial intelligence
For years, the race to build ever more powerful artificial intelligence followed a well-worn Silicon Valley principle: move fast and break things. But in a series of cascading events over a 10-day stretch, the largest AI labs found themselves reeling as their own creations threatened to break humanity itself. An Anthropic researcher quit the firm, warning that the pace of AI development poses an existential threat, possibly within a decade. Another researcher at the firm said the odds of human...
Psychology Lesson of the Day by Armistead Maupin, 'The world changes in direct proportion to the number of people willing to be honest about their lives' offers timeless inspiring wisdom on purpose, meaning, success, perspective, optimism
Armistead Maupin’s iconic statement is a powerful reminder that honesty can have consequences far beyond the person who speaks. Telling the truth about one's life can create vulnerability, but it can also create recognition, compassion and connection. The world does not change simply because people reveal personal information; it changes when authentic stories help others question assumptions, understand different experiences and see common humanity.
Reasons for Agarkar exit: Rohit Sharma future fiasco, difference of opinion with VVS Laxman
Agarkar’s exit was driven by differences over Rohit Sharma’s future and VVS Laxman, while his absence from a key review meeting added to BCCI concerns ahead of the 2027 ODI World Cup.
Four high courts get 14 judges, including Delhi HC
According to separate law ministry notifications, two judges and five additional judges have been appointed to the Delhi High Court while one judge has been appointed to the Jammu and Kashmir and Ladakh High Court.
Four high courts get 14 judges, including Delhi HC
According to separate law ministry notifications, two judges and five additional judges have been appointed to the Delhi High Court while one judge has been appointed to the Jammu and Kashmir and Ladakh High Court.
Asian Games 2026 Opening Ceremony Highlights: Manu Bhaker, Pawan Sehrawat Head India's Parade In Nagoya
Opening Ceremony Highlights: Manu Bhaker and Pawan Sehrawat led the Indian contingent at the athletes' parade.
'Critically important': Zelenskyy thanks Trump for Russia sanctions bill with nod to Lindsey Graham
Ukrainian President Volodymyr Zelenskyy thanked US President Donald Trump for signing the Lindsey O. Graham Sanctioning Russia and Iran Act of 2026, urging its provisions to be implemented “fully and swiftly” to increase pressure on Russia. He also paid tribute to the late Senator Lindsey Graham, after whom the legislation was named.
ABVP wins 3 DUSU posts; independent candidate Deepanshu Shokeen gets vice-president's position
ABVP won three of the four central panel posts in the Delhi University Students' Union election, while independent candidate Deepanshu Shokeen secured the vice-president's post. The Congress-backed NSUI failed to win any of the four positions. ABVP's Yash Dabas defeated NSUI's Vijai Shankar Meena by 2,053 votes in the presidential race.
4.9 magnitude quake jolts parts of Northeast
A magnitude 4.9 earthquake struck near Gyelpozhing in Bhutan at 4.01 pm on Saturday, with tremors felt in Guwahati and other parts of the Northeast.
4.9 magnitude quake jolts parts of Northeast
A magnitude 4.9 earthquake struck near Gyelpozhing in Bhutan at 4.01 pm on Saturday, with tremors felt in Guwahati and other parts of the Northeast.
Success Lesson of the Day by Dr. Seuss, 'Today was good. Today was fun. Tomorrow is another one' offers powerful wisdom on happiness, positivity, acceptance, inner peace
Quote of the day by Dr. Seuss teaches us to appreciate life without demanding perfection from it. Dr. Seuss turns the passage of time into something approachable: enjoy the day you have, remember the moments that made it special and then allow yourself to move forward. The quote encourages gratitude without complacency, optimism without unrealistic promises and enjoyment without guilt.
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.